Essential Pharma, an international pharmaceutical generics company dedicated to supplying well-established, “at risk” products to patients across multiple therapeutic areas, has been acquired by the company’s management supported by Gyrus Capital, a Swiss private equity group.
The transaction is designed to support Essential Pharma’s growth strategy based on identifying and acquiring proven generic medicines that are at risk of discontinuation by large pharmaceutical companies. The business aims to maintain the supply of these products on a sustainable basis and at a fair price. Essential Pharma plans to make further acquisitions to broaden both its product offering and geographic reach.
Essential Pharma has a long and successful track record of manufacturing drugs to the highest standards and working with health authorities in all countries in which it operates. Over the last 20 years, the company has built a portfolio of over 150 medicines across multiple disease areas and expanded its operations into over 20 countries including the UK, EU, Asia and New Zealand.